quote:

By 2005, reports of successful vaccine trials had already surfaced. Merck reported a successful preliminary trial of an HPV-16 vaccine for women in 2002. A 2004 report from Merck revealed that a vaccine showed promise in preventing up to 90 percent of four strains of the virus. In late 2004, an international clinical trial conducted by Dartmouth Medical School and the Norris Cotton Cancer Center reported a combination HPV-16/HPV-18 vaccine trial in women that was successful against persistent infection of HPV after 27 months. But even bigger news came in October of 2005, when Merck announced that a large clinical trial of a vaccine called Gardasil showed that women who received three vaccinations over a six-month period were 100 percent free of cervical cancer or precancerous lesions caused by HPV-16 and HPV-18. In women who were vaccinated only once during the six-month period, the vaccine was 97 percent effective. Merck also found the vaccine effective against HPV-6 and HPV-11. In order to become available to the public, Gardasil first needs approval from the U.S. Food and Drug Administration. While this will take time, especially given the current political climate, Merck hopes to make the vaccine available by late 2006. http://www.goaskalice.columbia.edu/3701.html

quote:

In late 2004, an international clinical trial conducted by Dartmouth Medical School and the Norris Cotton Cancer Center reported a combination HPV-16/HPV-18 vaccine trial in women that was successful against persistent infection of HPV after 27 months. But even bigger news came in October of 2005, when Merck announced that a large clinical trial of a vaccine called Gardasil showed that women who received three vaccinations over a six-month period were 100 percent free of cervical cancer or precancerous lesions caused by HPV-16 and HPV-18. In women who were vaccinated only once during the six-month period, the vaccine was 97 percent effective. Merck also found the vaccine effective against HPV-6 and HPV-11.